Featured Research

from universities, journals, and other organizations

Treatment For Rare Liver Disease Increases Mortality Risk

Date:
August 24, 2005
Source:
Center for the Advancement of Health
Summary:
Patients with primary biliary cirrhosis who are treated with methotrexate have an increased risk of death, according to a new systematic review of studies.

Patients with primary biliary cirrhosis who are treated withmethotrexate have an increased risk of death, according to a newsystematic review of studies.

In five randomized controlledtrials involving 457 people, the authors report that for patientstreated with methotrexate, as a single therapy or in combination withother drug treatment, pooled data showed a tendency toward an increasedrisk of death or liver transplantation. The brand names formethotrexate are Rheumatrex and Trexall.

“ We do not advocate theuse of methotrexate for patients with primary biliary cirrhosis,”conclude lead investigator Yan Gong, M.D., of Copenhagen UniversityHospital in Denmark and colleagues.
Their review appears in thelatest issue of The Cochrane Library, a publication of the CochraneCollaboration, an international organization that evaluates medicalresearch. Systematic reviews draw evidence based conclusions aboutmedical practice after considering both the content and quality ofexisting medical trials on a topic.

The reviewers highlight themortality and liver transplantation data from one long-term trial inwhich 11 of 30 patients in the methotrexate group died or underwentliver transplantation, compared with 7 of 30 patients in the placebogroup. Combining data from this and another trial other showed that“…methotrexate had a significantly detrimental effect on mortality.”

Methotrexateworks by blocking metabolism of cells and is effective in treatingcertain diseases characterized by abnormal cell growth, like breastcancer and psoriasis. Methotrexate is also widely used to treatrheumatoid arthritis.

Many drugs have been used to treat primarybiliary cirrhosis, with ursodeoxycholic acid (a bile acid) the mostfrequently used. In contrast to methotrexate, the reviewers note thatthey saw no “significant effect of ursodeoxycholic acid on mortality orliver transplantation.”

Three of the trials compared thetherapeutic use of ursodeoxycholic acid with and without methotrexate.One trial compared methotrexate to colchicine.

Primary biliarycirrhosis is an uncommon liver disease, and its cause is unknown,although it may be an autoimmune disease. Ninety percent of patientsare women and most are diagnosed after the age of 40. It can be aprecursor to cirrhosis of the liver or liver failure.

Studiesover the past 30 years indicate an increasing prevalence of thedisease, but little progress has been made in slowing diseaseprogression. Primary biliary cirrhosis has become a frequent cause ofliver morbidity, and patients with this condition are increasinglyundergoing liver transplantation.

The Cochrane reviewers notethat their conclusions could be qualified by the size of the data pooland the mixed quality of the studies involved. “Although the majorityof the evidence did not point to a beneficial effect of methotrexatefor patients with primary biliary cirrhosis,” they write, “we were notable to exclude the possibility for a beneficial effect in certainpatient groups. We advise that any new placebo-controlled trials withmethotrexate for patients with primary biliary cirrhosis should monitorharmful effects closely.

Keith Lindor, M.D., professor ofmedicine at the Mayo Medical School, says, “The most important findingin this review of the research is that methotrexate may indeed beharmful in the treatment of primary biliary cirrhosis. The drug shouldnot be used outside of clinical trials, which will not likely be donewith this drug because of the lack of efficacy and potential harm.”

###

Gong Y, Gluud C. Methotrexate for primary biliary cirrhosis. The Cochrane Database of Systematic Reviews 2005, Issue 3.


Story Source:

The above story is based on materials provided by Center for the Advancement of Health. Note: Materials may be edited for content and length.


Cite This Page:

Center for the Advancement of Health. "Treatment For Rare Liver Disease Increases Mortality Risk." ScienceDaily. ScienceDaily, 24 August 2005. <www.sciencedaily.com/releases/2005/08/050824081139.htm>.
Center for the Advancement of Health. (2005, August 24). Treatment For Rare Liver Disease Increases Mortality Risk. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2005/08/050824081139.htm
Center for the Advancement of Health. "Treatment For Rare Liver Disease Increases Mortality Risk." ScienceDaily. www.sciencedaily.com/releases/2005/08/050824081139.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins